Navigation Links
SLU research implicates natural toxin as triggering Parkinson's disease
Date:2/10/2011

ST. LOUIS In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.

In earlier research, Saint Louis University investigators found that DOPAL seemed to be responsible for killing healthy dopamine cells, which in turn causes Parkinson disease to develop. Now, research in an animal model gives them further reason to suspect the chemical as the culprit.

Parkinson's disease is a debilitating neurodegenerative movement disorder, affecting 2 percent of individuals older than age 65 and 4 to 5 percent older than 85 years. The disorder is due to a loss of dopamine neurons and is characterized by bradykinesia and tremors while at rest.

Saint Louis University investigators found that DOPAL, a breakdown product of dopamine, killed healthy dopamine cells and produced an animal model of Parkinson's disease, giving them evidence to suspect that DOPAL is the culprit.

Dopamine, a vital chemical that allows for coordinated function of neurons controlling the body's muscles and movements, is produced by nerve cells in the substantia nigra. When 80 percent of these cells die or become damaged, symptoms of Parkinson's disease begin to appear, including tremors, slowness of movement, rigidity and stiffness, and difficulty with balance.

Lead researcher, W. Michael Panneton, Ph.D., professor of pharmacological and physiological science at Saint Louis University School of Medicine, says the research offers a big step forward in the understanding of Parkinson disease.

"In Parkinson disease, we knew that the death of dopamine cells is responsible for patients' symptoms," said Panneton. "But no one knew why the cells are dying."

From a cellular perspective, doctors know some pieces of the puzzle. They know that Parkinson patients have a loss of dopamine neurons in a part of the brain called the substantia nigra, leading to severe dopamine loss in another part of the brain called the striatum, and the aggregation of a protein called alpha-synuclein.

Alpha-synuclein is found throughout the brain. In some people, the protein clumps together. Researchers found that it is DOPAL that causes alpha-synuclein protein in the brain to aggregate. This induces further increases of DOPAL leading to the death of the dopamine-producing cells, which in turn causes Parkinson's symptoms to develop.

Currently, the main approach to Parkinson's disease is to treat symptoms by replacing dopamine that's lost when the cells die. This approach however does not prevent the loss of dopamine neurons causing Parkinson's disease.

This new research opens up promising new research avenues to prevent dopamine neuron loss and the progression of Parkinson's disease.


'/>"/>

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University
Source:Eurekalert

Related biology news :

1. New research helps explain how progesterone prevents preterm birth
2. New research helps explain how progesterone preventspreterm birth
3. Single-cell marine predators unique survival mechanisms revealed: UBC research
4. Research helps drivers cut fuel use
5. Boston University School of Medicine researchers receive NIMH brain awards
6. Research team honored for innovative science to advance cancer research
7. Research proves new soybean meal sources are good fish meal alternatives
8. Springer and the French National Institute for Agricultural Research INRA team up
9. Research links 29 genome regions with common form of inflammatory bowel disease
10. Just in time for Valentines Day: UNC researchers identify a gene critical for heart function
11. Johns Hopkins researchers capture jumping genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: